Literature DB >> 24791730

Low varicella-related consultation rate in the Netherlands in primary care data.

Alies van Lier1, Jolanda van Erp2, Gé A Donker3, Nicoline A T van der Maas4, Miriam C J M Sturkenboom5, Hester E de Melker6.   

Abstract

BACKGROUND: In the Netherlands, a relatively low varicella disease burden compared to other European countries is observed within routine surveillance. To validate this, we estimated the varicella-related consultation rate using The Integrated Primary Care Information database.
METHODS: In this retrospective cohort study, varicella patients in 2006-2008 were identified by the International Classification of Primary Care (A72) and free text in the electronic medical records, and manually reviewed to be categorised as 'varicella' or 'probable varicella'. The incidence of GP-consultation, specialist referral, emergency department contact and hospitalisation due to varicella was calculated, standardised to the Dutch population.
RESULTS: We identified 1881 varicella cases (2348 including probable cases), 14 patients were hospitalised. The overall incidence of GP-consultation due to varicella per 100,000 person-years was at least 281 (95%CI 268-294) and when probable cases were also included at maximum 354 (95%CI 340-369). The overall incidence of specialist referral, emergency department contact and hospitalisation per 100,000 person-years was 3.9 (95%CI 2.7-5.6), 2.5 (95%CI 1.5-4.0) and 2.0 (95%CI 1.2-3.4) respectively.
CONCLUSIONS: This study confirms the relatively low disease burden due to varicella in the Netherlands. In this study, using primary care data, similar incidences of GP consultation and referral to secondary care due to varicella were found as in routine surveillance. The lower varicella-related consultation rate might be linked to more conservative GP consultation behaviour in the Netherlands, and the relatively young age of infection. This is highly relevant for the decision-making process whether or not to introduce universal childhood varicella vaccination in the Netherlands.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Complications; General practitioner; Hospital admission; Incidence; Varicella

Mesh:

Year:  2014        PMID: 24791730     DOI: 10.1016/j.vaccine.2014.04.034

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  The burden of chickenpox disease in Sweden.

Authors:  Katarina Widgren; Johan Giesecke; Lars Lindquist; Anders Tegnell
Journal:  BMC Infect Dis       Date:  2016-11-10       Impact factor: 3.090

2.  Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization.

Authors:  Margarita Riera-Montes; Kaatje Bollaerts; Ulrich Heininger; Niel Hens; Giovanni Gabutti; Angel Gil; Bayad Nozad; Grazina Mirinaviciute; Elmira Flem; Audrey Souverain; Thomas Verstraeten; Susanne Hartwig
Journal:  BMC Infect Dis       Date:  2017-05-18       Impact factor: 3.090

Review 3.  Factors influencing the development of primary care data collection projects from electronic health records: a systematic review of the literature.

Authors:  Marie-Line Gentil; Marc Cuggia; Laure Fiquet; Camille Hagenbourger; Thomas Le Berre; Agnès Banâtre; Eric Renault; Guillaume Bouzille; Anthony Chapron
Journal:  BMC Med Inform Decis Mak       Date:  2017-09-25       Impact factor: 2.796

4.  Disease burden of varicella versus other vaccine-preventable diseases before introduction of vaccination into the national immunisation programme in the Netherlands.

Authors:  Alies van Lier; Brechje de Gier; Scott A McDonald; Marie-Josée J Mangen; Maarten van Wijhe; Elisabeth A M Sanders; Mirjam E Kretzschmar; Hans van Vliet; Hester E de Melker
Journal:  Euro Surveill       Date:  2019-05

5.  Economic burden of varicella in Europe in the absence of universal varicella vaccination.

Authors:  Manjiri Pawaskar; Estelle Méroc; Salome Samant; Elmira Flem; Goran Bencina; Margarita Riera-Montes; Ulrich Heininger
Journal:  BMC Public Health       Date:  2021-12-21       Impact factor: 3.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.